564TiP A phase Ib dose-escalation study of ZN-c5, an oral selective estrogen receptor degrader (SERD), in combination with abemaciclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer
Georgina Keogh, Steven W. Papish, W. Piskorski, Małgorzata Ułańska, Bradford E. Jackson, Matt Suster, Mieke Ptaszynski, Lida A. Mina
Topics & Concepts
MedicineEstrogen receptorBreast cancerOncologyInternal medicineSelective estrogen receptor modulatorCancerCancer researchHER2/EGFR in Cancer ResearchAdvanced Breast Cancer TherapiesChronic Lymphocytic Leukemia Research